Table 1 Baseline characteristics of JIA patients according to ever achieving clinical remission of the disease
|  | Active Disease (n = 62) | Clinical Remission (n = 144) | TOTAL (n = 206) | p |
|---|---|---|---|---|
Female sex, n (%) | 44 (71) | 103 (72) | 147 (71) | 0.531 |
Caucasian ethnicitya, n (%) | 55 (89) | 136 (94) | 191 (93) | 0.016 |
JIA subtype n (%) | ||||
 Oligoarticular | 24 (39) | 83 (58) | 107 (52) | 0.285 |
  Persistenta | 14 (58) | 70 (84) | 84 (41) | 0.016 |
  Extended | 10 (42) | 13 (16) | 23 (12) |  |
 Poliarticular RF - | 9 (15) | 11 (8) | 20 (10) |  |
 Poliarticular RF + | 2 (3) | 5 (4) | 7 (3) |  |
 Psoriatic | 6 (10) | 11 (8) | 17 (8) |  |
 Systemic | 4 (7) | 13 (9) | 17 (8) |  |
 Enthesitis-related arthritis | 13 (21) | 17 (12) | 30 (15) |  |
 Undifferentiated | 3 (5) | 5 (4) | 8 (4) |  |
No uveitis, n (%) | 47 (76) | 116 (81) | 163 (79) | 0.277 |
No comorbiditiesa, n (%) | 40 (65) | 125 (87) | 165 (80) | 0.001 |
Positive ANA, n (%) | 36 (58) | 103 (72) | 139 (68) | 0.067 |
Positive RF, n (%) | 3 (5) | 6 (4) | 9 (4) | 0.536 |
HLA B27 presence, n (%) | 13 (21) | 18 (13) | 31 (15) | 0.073 |
No AE with DMARDa, n (%) | 30 (48) | 108 (75) | 138 (67) | 0.001 |
No biologic DMARDa, n (%) | 22 (36) | 84 (58) | 106 (52) | 0.002 |